А rare complication, associated with the use of modern immunooncology drugs - kidney injury
https://doi.org/10.62546/3034-1477-2024-2-3-62-69
Abstract
Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and programmed death protein 1 (PD-1) or its ligand (PD-L1), are a new generation of immuno-oncological drugs that to date have demonstrated efficacy in a number of malignancies. The mechanism of ICIs action consist in the potentiation of the immune response by eliminating the tumor cells inhibitory effect on the T-lymphocytes activation. However, excessive immune system activation can cause the development of a special class of immune-related adverse events (irAEs) involved a wide variety of organs and systems, including the kidneys. Despite the fact that immunomediated kidney injury caused by ICI therapy develops quite rarely (2–15%), it can be serious and determine the patient’s prognosis, which necessitates early diagnosis and timely start of treatment. In this regard, awareness of the manifestations of ICI-associated renal irAEs is particularly relevant not only for oncologists and for nephrologists, but for doctors of other specialties.
Keywords
immunotherapy,
immune checkpoint inhibitors,
rare immune-mediated adverse events,
renal
immune-related adverse events,
acute kidney injury
Supporting agencies: The article was prepared without sponsorship.
About the Authors
R. V. Orlova
St. Petersburg State University; St. Petersburg City Clinical Oncology Dispensary
Russian Federation
Russian Federation
7/9 Universitetskaya Emb., 199034; 56 Veteranov Ave., St. Petersburg 193318
N. P. Belyak
St. Petersburg State University; St. Petersburg City Clinical Oncology Dispensary
Russian Federation
Russian Federation
7/9 Universitetskaya Emb., 199034; 56 Veteranov Ave., St. Petersburg 193318
E. A. Mgar
St. Petersburg State University
Russian Federation
Russian Federation
Mgar Ekaterina Andreevna
7/9 Universitetskaya Emb., 199034
References
1. Hodi F.S., O’Day S.J., McDermott D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma // N. Engl. J. Med. 2010. Vol. 363, No 8. P. 711–723. https: //doi.org/10.1056/NEJMoa1003466.
2. Izzedine H., Mateus C., Boutros C. et al. Renal effects of immune checkpoint inhibitors // Nephrol. Dial. Transplant. 2017. Vol. 32, No. 6. P. 936–942. doi: 10.1093/ndt/gfw382.
3. Hu R., Chen M., Xu Y. et al. Renal immune-related adverse events of immune checkpoint inhibitor // Asia Pac J. Clin Oncol. 2020. Vol. 16, No. 6. P. 305–311. doi: 10.1111/ajco.13387.
4. Spanou Z, Keller M, Britschgi M, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis // J. Am. Soc. Nephrol. 2006. Vol. 17, No. 10. P. 2919–2927. doi: 10.1681/ASN.2006050418.
5. Wuthrich R.P., Glimcher L.H., Yui M.A. et al. MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells // Kidney Int. 1990. Vol. 37, No. 2. P. 783–792. doi: 10.1038/ki.1990.46.
6. Francisco L.M., Sage P.T., Sharpe A.H. The PD-1 pathway in tolerance and Autoimmunity // Immunol. Rev. 2010. Vol. 236. P. 219–242. doi: 10.1111/j.1600-065X.2010.00923.
7. Murakami N., Motwani S., Riella L.V. Renal complications of immune checkpoint blockade // Curr. Probl. Cancer. 2017. Vol. 41, No. 2. P. 100–110. doi: 10.1016/j.currproblcancer.2016.12.004.
8. Schoop R., Wahl P., Le Hir M. et al. Suppressed T-cell activation by IFN- gamma-induced expression of PD-L1 on renal tubular epithelial cells // Nephrol. Dial. Transplant. 2004. Vol. 19, No. 11. P. 2713–2720. doi: 10.1093/ndt/gfh423.
9. Marco T., Anna P., Annalisa T. et al. The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma // Ther. Adv. Med. Oncol. 2019. Vol. 11, No. 17. P. 179–186. doi: 10.1177/1758835919875549.
10. Herrmann S.M., Perazella M.A. Immune Checkpoint Inhibitors and Immune- Related Adverse Renal Events // Kidney Int Rep. 2020. Vol. 5, No. 8. P. 1139–1148. doi: 10.1016/j.ekir.2020.04.018.
11. Zha H., Han X., Zhu Y. et al. Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade // Oncoimmunology. 2017. Vol. 6, No. 10. P. 1349–1420. doi: 10.1080/2162402X.2017.1349587.
12. Postow M.A., Sidlow R., Hellmann M.D. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade // N. Engl. J. Med. 2018. Vol. 378, No. 2. P. 158–168. doi: 10.1056/NEJMra1703481.
13. Champiat S., Lambotte O., Barreau E. et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper // Ann. Oncol. 2016. Vol. 27, No 4. P. 559–574. doi: 10.1093/annonc/mdv623.
14. Voskens C.J., Goldinger S.M., Loquai C. et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network // PLoS One. 2013. Vol. 8, No. 1. P. 537–545. doi: 10.1371/journal.pone.0053745.
15. Cortazar F.B., Marrone K.A., Troxell M.L. et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors // Kidney Int. 2016. Vol. 90, No. 3. P. 638–647. doi: 10.1016/j.kint.2016.04.008
16. Hofmann L., Forschner A., Loquai C. et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy // Eur. J. Cancer. 2016. Vol. 60. P. 190–209. doi: 10.1016/j.ejca.2016.02.025.
17. Perazella M.A., Shirali A.C. Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future // J. Am. Soc. Nephrol. 2018. Vol. 29, No. 8. P. 2039–2052. doi: 10.1681/ASN.2018050488.
18. Mamlouk O., Selamet U., Machado S. et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center Experience // J. Immunother. Cancer. 2019. Vol. 7, No. 1. P.225–229. doi: 10.1186/s40425- 018-0478-8.
19. Patel V., Elias R., Formella J. et al. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma // J. Immunother. Cancer. 2020. Vol. 8, No. 2. P. 198–202. doi: 10.1136/jitc-2020-001198.
20. Seethapathy H., Zhao S., Chute D.F. et al. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors // Clin. J. Am. Soc. Nephrol. 2019. Vol. 14, No. 12. P. 1692–1700. doi: 10.2215/CJN.00990119.
21. Manohar S., Kompotiatis P., Thongprayoon C. et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis // Nephrol. Dial. Transplant. 2019. Vol. 34, No. 1. P. 108– 117. doi: 10.1093/ndt/gfy105.
22. Cortazar F.B., Kibbelaar Z.A., Glezerman I.G. et al. Clinical Features and Outcomes of Immune Checkpoint InhibitorAssociated AKI: A Multicenter Study // J. Am. Soc. Nephrol. 2020. Vol. 31, No. 2. P. 435–446. doi: 10.1681/ASN.2019070676.
23. Wanchoo R., Karam S., Uppal N.N. et al. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review // Am J. Nephrol. 2017. Vol. 45, No. 2. P. 160–169. doi: 10.1159/000455014.
24. Meraz-Muñoz A., Amir E., Ng P. et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes // J. Immunother. Cancer. 2020. Vol. 8, No. 1. P. 467–472. doi: 10.1136/jitc-2019-000467.
25. Zakharova E.V., Ostroumova O.D. Onconephrology: Anticancer Drug-induced Kidney Damage. Nephrology and Dialysis, 2020, Vol. 22, No. 3, рр. 383–395 (In Russ.)]
26. Shirali A.C., Perazella M.A., Gettinger S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients // Am. J. Kidney Dis. 2016. Vol. 68, No. 2. P. 287–291. doi: 10.1053/j.ajkd.2016.02.057.
27. Belliere J., Meyer N., Mazieres J. et al. Acute interstitial nephritis related to immune checkpoint inhibitors // Br. J. Cancer. 2016. Vol. 15, No. 12. P. 1457–1461. doi: 10.1038/bjc.2016.358.
Review
For citations:
Orlova R.V., Belyak N.P., Mgar E.A. А rare complication, associated with the use of modern immunooncology drugs - kidney injury. Clinical Case in Oncology. 2024;2(3):62-69. (In Russ.) https://doi.org/10.62546/3034-1477-2024-2-3-62-69
Views:
94
Email this article 